Skip to main content
OpenTrials
Completed

NCT Number: NCT07434362

Serum Endocan, Alarin, and Galanin-Like Peptide Levels in Diabetic Retinopathy

This prospective cross-sectional study aims to evaluate the association between serum endocan, alarin, and galanin-like peptide levels and the stages of diabetic retinopathy (DR), as well as their relationship with optical coherence tomography (OCT) findings.

A total of 120 participants will be included: 30 patients without diabetic retinopathy, 30 with non-proliferative diabetic retinopathy, 30 with proliferative diabetic retinopathy, and 30 healthy control subjects. In addition to routine preoperative blood sampling, an additional 5 mL of venous blood will be collected for biomarker analysis using ELISA. Macular and peripapillary retinal nerve fiber layer measurements will be obtained using OCT. Serum biomarker levels will be compared across DR stages and analyzed for correlation with OCT parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Retinopathy Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Endocrine System Diseases Eye Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Retinal Diseases Retinal Microvascular Disease Vascular Diseases

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fethi Sekin City Hospital

Elâzığ, Elaziğ, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 40 to 70 years.
  • Diagnosis of diabetes mellitus (for diabetic groups).
  • For control group: absence of diabetes mellitus and no retinal or optic nerve pathology.

Exclusion criteria

  • Presence of systemic or ocular inflammatory disease.
  • Any ocular disease other than diabetic retinopathy that may affect the retina or optic nerve.

Treatment and study plan

Venous Blood Sampling

Procedure

Collection of 5 mL of venous blood in addition to routine preoperative sampling for the measurement of serum endocan, alarin, and galanin-like peptide levels using ELISA.

Optical Coherence Tomography (OCT)

Procedure

Non-invasive optical coherence tomography imaging of the macula and peripapillary retinal nerve fiber layer using a Canon OCT device for structural retinal assessment.

Primary outcomes

  1. Serum Endocan Level

    Time frame: At baseline (preoperative blood sampling)

    Serum endocan concentration measured using ELISA and compared across diabetic retinopathy stages.

  2. Serum Alarin Level

    Time frame: At baseline

    Serum alarin concentration measured by ELISA and analyzed according to diabetic retinopathy severity.

  3. Serum Galanin-Like Peptide Level

    Time frame: At baseline

    Serum galanin-like peptide concentration measured using ELISA and compared between study groups.

Sponsors and collaborators

Lead sponsor

Elazıg Fethi Sekin Sehir Hastanesi

Other

Registry information

Official study title

Association of Serum Endocan, Alarin, and Galanin-Like Peptide Levels With Diabetic Retinopathy Stages and Optical Coherence Tomography (OCT) Findings

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 25, 2026
Registry last updated
Feb 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.